Wockhardt gets US FDA approval for pa...
Home  »  Community News  »  Wockhardt gets US FD...
Wockhardt gets US FDA approval for pain medication oxycodone liquid
Pharma News

Wockhardt has received final approval from the US FDA for marketing 5mg/5ml of oxycodone HCI liquid which is used in treatment of moderate to severe acute and chronic pain. The company is launching the product soon and will be amongst the few generic versions of this product in the market.

Dr Habil Khorakiwala, founder chairman & chief executive officer, Wockhardt group, said “We are delighted to receive this ANDA approval for our oxycodone liquid. We have filed several ANDAs over the last couple of years from our Morton Grove Pharmaceuticals facility in Illinois, USA, especially for liquid products. This is only the first of few others we expect soon.”

The total market for this product in the US is projected by IMS at about $58 million. Oxycodone is used extensively in management of pain, especially in opioid tolerant patients. Wockhardt already markets several other controlled substance products in the US and generally has a leading presence in the liquid formulations segment.

In the US generic pharma market, Wockhardt has been consistently growing market shares for all its products. In many instances, Wockhardt, by virtue of being amongst the few players to market technically challenging products, has reaped the advantage of being an early entrant.

Leave a reply

You must be logged in to post a comment.